Blog
RSS FeedPosted by Michael Wonder on 18 Nov 2015
Insulin degludec plus liraglutide: again no hint of added benefit in type 2 diabetes says IQWiG
16 November 2015 - The manufacturer presented no relevant data for the assessment of the added benefit of insulin degludec/liraglutide versus ...
Posted by Michael Wonder on 18 Nov 2015
Amgen's cholesterol-buster Repatha turned down for NHS use
18 November 2015 - NICE has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option ...
Posted by Michael Wonder on 18 Nov 2015
NICE says 'no' to personalised bowel cancer drugs
18 November 2015 - NICE has published interim guidance barring patients with advanced bowel cancer from routine NHS access to Merck ...
Posted by Michael Wonder on 18 Nov 2015
Nivolumab in non-small cell lung cancer: indication of major added benefit for under-75-year-olds
16 November 2015 - According to the findings, there is an indication of major added benefit of nivolumab over the appropriate ...
Posted by Michael Wonder on 17 Nov 2015
Drug Utilisation Sub Committee outcome statement
13 November 2015 - The outcome statement for the October 2015 Drug Utilisation Sub Committee meeting is now available. ...
Posted by Michael Wonder on 16 Nov 2015
FDA approves Darzalex for patients with previously treated multiple myeloma
16 November 2015 - Today the U.S. FDA granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who ...
Posted by Michael Wonder on 16 Nov 2015
Public Summary Documents - PBAC July 2015 meeting
13 November 2015 - Additional Public Summary Documents from the July 2015 PBAC meeting are now available. ...
Posted by Michael Wonder on 12 Nov 2015
FDA approves Cotellic as part of combination treatment for advanced melanoma
10 November 2015 - The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib ...
Posted by Michael Wonder on 12 Nov 2015
November 2015 decisions news release
9 November 2015 - New treatments for skin cancer, ovarian cancer and deep vein thrombosis have been accepted for routine ...
Posted by Michael Wonder on 05 Nov 2015
NICE not in favour of drug for neuroblastoma
5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin ...
Posted by Michael Wonder on 05 Nov 2015
FDA approves new treatment for HIV
5 November 2015 - The U.S. FDA today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) ...
Posted by Michael Wonder on 05 Nov 2015
FDA approves Nucala to treat severe asthma
4 November 2015 - The U.S. FDA has approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment ...
Posted by Michael Wonder on 05 Nov 2015
Edoxaban tosylate: considerable additional benefit for certain patients
2 November 2015 - IQWiG finds an indication of a considerable additional benefit in comparison with vitamin K antagonists for the ...
Posted by Michael Wonder on 04 Nov 2015
CADTH recommends Entyvio for patients with ulcerative colitis
28 October 2015 - CADTH's CDEC has recommended that vedolizumab be listed for the treatment of adult patients with moderately ...
Posted by Michael Wonder on 04 Nov 2015
NICE gives green light to dry eye disease treatment in final draft guidance
4 November 2015 - NICE has published final draft guidance recommending ciclosporin (Ikervis) manufactured by Santen Pharmaceutical) for treating severe keratitis ...